-
Mashup Score: 1
Interview with David Henry MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Pretreatment with ibrutinib facilitates rapid drug desensitization in a difficult case of brentuximab vedotinâinduced anaphylaxis - 1 year(s) ago
Rapid drug desensitization (RDD) is a technique used to induce transient tolerance to the required medication by gradually increasing the dose of the culprit drug until the therapeutic dosage can be tolerated. RDD is mainly performed in patients who have developed IgE-mediated drug reactions and in whom alternative medicines are unavailable. The possible explanations for mast cell…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Bendamustine and Brentuximab Vedotin Combo Shows High Activity in R/R PTCL | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination January 18, 2023 Treatment with a combination of bendamustine and brentuximab vedotin (BBv) was associated with high rates of response and encouraging improvements in survival in patients with relapsed or…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkinâs Lymphoma | NEJM - 1 year(s) ago
Original Article from The New England Journal of Medicine â Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkinâs Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâs Lymphoma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine â Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâs Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Editorial from The New England Journal of Medicine â A Better Treatment for Advanced-Stage Hodgkinâs Lymphoma?
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâs Lymphoma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine â Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâs Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâs Lymphoma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine â Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâs Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41% - 2 year(s) ago
Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Costâeffectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma | Journal of Comparative Effectiveness Research - 2 year(s) ago
Aim: To assess the costâeffectiveness of brentuximab vedotin (BV) versus physicianâs choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned-survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or…
Categories: Hem/Oncs, Latest HeadlinesTweet
#Nivolumab Plus #Brentuximab Vedotin for Low-Risk Relapsed Classic #HodgkinLymphoma Check out my practice update! đhttps://t.co/9tlCmoBmg3